drugset / Trial / NCT00171145

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

NCT00171145

Phase 3 Completed 445 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.

Timeline

Start
2004-04
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Darifenacin Small molecule 15 mg

Indications